Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Entia Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2016 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Entia Biosciences's 3-Year ROIIC % or its related term are showing as below:
ERGO's 3-Year ROIIC % is not ranked *
in the Biotechnology industry.
Industry Median: -4.82 * Ranked among companies with meaningful 3-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Entia Biosciences 3-Year ROIIC % Related Terms
Entia Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Entia Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERGO vs OBMP, NSPX, ATRX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Entia Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entia Biosciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entia Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Entia Biosciences's 3-Year ROIIC % falls into.
Entia Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2016 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.167 (Dec. 2016) - -2.682 (Dec. 2013) )
/
( 0.951 (Dec. 2016) - 0.829 (Dec. 2013) )
=
1.515
/
0.122
=
1,241.80%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Entia Biosciences (ERGO) has a 3-Year ROIIC % of 0.00 as of Dec. 2016. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Entia Biosciences and its competitors.
Is Entia Biosciences' 3-Year ROIIC % too high?
Entia Biosciences' current 3-Year ROIIC % is 0.00.
How does Entia Biosciences' 3-Year ROIIC % compare to OBMP and NSPX?
Entia Biosciences' 3-Year ROIIC % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Entia Biosciences and its competitors. Entia Biosciences's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current 3-Year ROIIC % is 0.00 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERGO has been successfully added to your 
